Tenet's 48% Sprint Into a Quarter It Called 'Mechanical'
The headline raise is mostly Conifer transition noise; the real bull case is a sum-of-parts USPI argument management is making in public without quite making it
THC · Earnings Call · 2026-10-29
A beat that management itself refuses to take credit for
Tenet's third quarter reads like a blowout on the tape: net operating revenue of $5.6 billion, consolidated adjusted EBITDA of $1.355 billion, adjusted diluted EPS up 80% to $6.40, and a $195 million midpoint raise to full-year EBITDA guidance of $5.05–$5.2 billion. Then Saumya Sutaria spends the first three minutes of the call dismantling it. Of the quarter's earnings, $147 million was transition activities at Conifer — $97 million of revenue recognized earlier than planned (explicitly a shift out of Q4, not incremental to the year) plus $50 million of expense reductions that landed ahead of schedule. The CFO's own framing is unusually candid for a company guiding up 4%:He is right, and the arithmetic confirms it. Sutaria notes that “over 40% of our total guidance increase for this year is from fundamental outperformance” — Saumya Sutaria, Chief Financial Officer · 2026-10-29 — which is a careful way of saying the majority of it is not. The remaining lever was $32 million of out-of-period supplemental Medicaid revenue. So the honest decomposition of a $195 million raise is: roughly two-thirds accounting timing and catch-up payments, roughly one-third operating.the change in our estimates for guidance ranges was pretty mechanical this quarter, where it was virtually all to do with the onetime items as well as the revenue recognition piece that we already mentioned, plus the out of period Medicaid.
Why the price action refuses to care
None of that has dented the stock. Shares are up 47.9% over 90 trading days and sit just 3.6% below an all-time high set on August 21st, on a $21.8 billion market cap. That is the tell: nobody is buying Tenet for Q3 2026. They are buying a de-levered, cash-gushing business at a multiple that its own CEO plainly thinks is wrong. Price to net income of 5.1x is not a hospital multiple. It is a distressed multiple attached to a business that repurchased 8 million shares for $1.615 billion year to date, $255 million of it last quarter alone, and now has effective net cash of -$10.9 billion after retiring $2 billion of 2027/2028 notes with new 2034 paper. Leverage is 2.11x, or 2.58x less NCI. Analyst A.J. Rice put the question that everyone in the room was thinking: two nonprofit health systems just paid premiums for surgery-center assets that exceed the multiple the market pays for all of Tenet, including USPI. Sutaria's answer was the closest thing to an activist slide deck delivered verbally: “especially at our attractive valuation multiple in light of recent comparable multiples for combination ASC hospital platforms.” — Saumya Sutaria, Chief Financial Officer · 2026-10-29 Tenet has created a brand-new keyword for itself this quarter — ASC Hospital combination platforms — and it is not an accident. The CEO is publicly benchmarking his own equity against transaction comps and concluding that the cheapest acquisition available to him is his own stock.USPI: the engine, and the gap
Strip away Conifer and the operating story is genuinely good, just narrower than the headline. USPI generated $537 million of EBITDA, up 9.1%, at a 39.2% margin — same-facility revenue up 4.5%, net revenue per case up 6.1%, case volume deliberately down 1.5% as low-acuity work is culled. Total joints grew 12.8% same-store, the strongest quarter of the year, and the migration is explicitly one-way: from hospital outpatient departments into freestanding, lower cost settings. That is the high acuity thesis compounding, and it echoes a theme showing up across this week's reporters — Orthopedic Surgery and robotic-surgery commentary from device makers is running hot while acute-care volumes stay merely okay. Capital is following. Over $100 million deployed into USPI development in the quarter alone, four de novos already open this year, and management flagging a pipeline that mostly arrives without a competitive auction. When Rice asked whether the reacceleration in joints was share taken from hospitals, the answer was unambiguous — it is site-of-care migration, and Tenet owns both ends of the funnel.The headwind that is burning off — and the one being deferred
For four straight quarters, exchange headwinds was the dominant risk in this story. In Q3, exchange admissions and revenues fell 18%, but exchange is now only about 5.5% of consolidated revenue, down from roughly 7% a year ago and 8.4% of admissions in Q3 2025. Sutaria's read: “largely Q3 is a stabilization message from Q2” — Saumya Sutaria, Chief Financial Officer · 2026-10-29 — the deterioration decelerated rather than reversed. Compare that to July, when the tone was defensive and the assumption was continued erosion:That trade worked out. Which is precisely why the new overhang matters more. Exchange was a quantifiable, contracting problem. What replaces it — HR 1, Medicaid work requirements, state-directed payment reform — is neither. Tenet disclosed that “about 60% of our admissions that are from expansion states” — Sun K. Park, Chief Executive Officer · 2026-10-29, with $356 million of supplemental Medicaid payments in the quarter. Asked for long-term segment targets, Sutaria deferred “until there is full clarity about what is going to happen vis a vis HR1” — Saumya Sutaria, Chief Financial Officer · 2026-10-29. He has made this argument before, more bluntly, insisting that state-directed money represents services actually built: “this whole notion that somehow state-directed payment program monies... are not monies that are earned, doesn't make a lot of sense to me” — Saum Sutaria, CEO or President · 2026-07-24. It is a fair argument and an unresolved one.We expect the overall market trends that we saw in Q2 to roughly continue into Q3 and Q4 rest of the year, which is why we didn't change our guidance.